| Autor: |
Plasencia C, Graham KK, Droller DG |
| Zdroj: |
Journal of Infectious Disease Pharmacotherapy; 2001, Vol. 5 Issue 2, p1-10, 10p |
| Abstrakt: |
We describe a patient with cerebral toxoplasmosis who was treated with high-dose intravenous azithromycin salvage therapy and we review the literature on azithromycin for the treatment of cerebral toxoplasmosis. A literature review of case reports and studies reveals limited experience with azithromycin. Evaluation of these reports demonstrates successful treatment with azithromycin 150 mg-1200 mg PO daily in combination with pyrimethamine, sulfadiazine, doxycycline, and clindamycin. Patients receiving azithromycin 500 mg (low dose) as monotherapy experienced worsening of intracerehral lesions indicating a dose-response relationship. With the availability of the intravenous form, azithromycin IV is now an option to assure rapid therapeutic drug concentrations in the acute management of cerebral toxoplasmosis. Azithromycin is a potential salvage therapy for the treatment of cerebral toxoplasmosis when given as 150-1200 mg in combination therapy; however, controlled clinical trials are needed to compare azithromycin to standard therapies to determine its true role in the treatment of cerebral toxoplasmosis. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
